Cancer – ADVL1414: Phase 1 Study of Selinexor, a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Condition or Therapy:
Solid tumors, high-grade gliomas
Cancer and Blood Disorders
Study Number: ADVL1414
What is the goal of this study?
Researchers want to determine the correct dosage of selinexor in treating patients with solid and CNS tumors.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between 12 months and 21 years old, and
- have recurrent or refractory tumors, including lymphoma and CNS tumors and high-grade glioma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.